The Latest Updates From the Gene-Editing Clinical...
Feb. 26, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Navega Therapeutics
Company Type: Therapeutic development
Main focus: Developing novel therapeutics via zinc finger nuclease - and CRISPR-based epigenome regulation
Company stage: Pre-clinical
Diseases: Small fiber neuropathy, primary erythromelalgia and other rare diseases
Genome-editing tool: Zinc finger nuclease (ZFN)- and CRISPR-based epigenome regulation
Funding stage: Grant
Location: San Diego, California, USA
Website: navegatx.com/en
Pipeline:
Partners:
Navega Therapeutics is a pre-clinical biotechnology company based in California, USA, focused on treating chronic pain through epigenome-editing technologies. By leveraging zinc finger nuclease (ZFN) and CRISPR-based epigenome editing, Navega has developed a patented, non-permanent gene therapy designed to be highly specific, long-lasting, and non-addictive. Their approach targets a naturally-occurring mutation associated with increased pain tolerance, offering a novel, gene-editing alternative to conventional pain management. Navega aims to provide a novel solution for chronic pain linked to rare diseases.
